TIDMFDBK
RNS Number : 6261L
Feedback PLC
14 September 2021
Feedback plc
Feedback enters into Memorandum of Understanding with
Qure.ai
-- Partnership to assess technical collaboration between Bleepa and Qure.ai technologies
-- Qure.ai is a specialist in AI-powered radiology solutions
-- Early exploration of joint solution for TB screening in India, Africa and South-East Asia
London, 14 September 2021 : Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist clinical communication company,
announces that it has signed a Memorandum of Understanding ("MoU")
with Qure.ai, an AI solution provider developing decision support
tools for medical imaging professionals.
Pursuant to the agreement, Qure.ai and Feedback will explore the
use of Bleepa as a digital infrastructure partner to access X-rays
and other medical imaging studies from multiple care settings, for
processing by Qure.ai's AI algorithms, and as a vehicle for
presenting the report generated back to clinicians. Bleepa will
enable truly on-the-go access to the Qure.ai product suite through
a clinician's own mobile devices, facilitating access to AI
interpreted patient imaging from any location on any
internet-connected device in under a few minutes.
Qure.ai uses artificial intelligence to make healthcare more
accessible and affordable and has a number of products addressing
multiple clinical areas. Qure.ai's qXR technology is capable of
automated chest X-ray interpretation to help radiologists read
X-rays in a faster and more accurate way. It can detect about 30
different abnormal findings on a chest X-ray, including screening
of tuberculosis, lung nodules and quantify the progression of lung
infection in various conditions such as Covid-19. Qure.ai
additionally has AI tools like the qER relating to cross-sectional
imaging which interprets head CT scans for triaging and early
diagnosis of stroke and traumatic brain injuries.
The partnership will evaluate product opportunities in multiple
care settings both in India and the UK. An initial focus for the
partnership is to support the delivery of TB screening to rural
populations within India which rely on chest X-ray images for
diagnosis. Currently, in rural settings it is difficult to get
X-rays formally reported by a radiologist because there is no
digital infrastructure to enable image sharing. Bleepa can
facilitate the upload of the X-ray or in-field images for Qure.ai's
technology to assess on the spot. It can also display the
AI-generated report to clinicians, enabling treatment to be given
immediately and within the same appointment, even in rural
settings. This combined solution will enable the TB screening
programme to expand across disparate locations in India.
Qure.ai has deployments across 45+ countries and processes more
than 15,000 scans daily. Qure's qXR is CE marked and the World
Health Organisation has endorsed it for TB screening and triage as
an alternate of human readers.
The companies are also actively looking at opportunities in the
UK following Qure.ai's appointment to the NHSx AI Award programme.
Given the breadth of capabilities of both products, there are
applications for the solutions in multiple care settings.
Dr Tom Oakley, CEO of Feedback, said:
"We are delighted to be working with Qure.ai; there are multiple
large commercial opportunities and this is only the beginning to
forging a pathway for a new global regime of diagnostic testing and
screening. The combination of Qure.ai's AI reporting capabilities
through Bleepa's instant and secure communications platform has the
potential to provide timely, efficient and cost-effective care
across a number of clinical settings. The companies are
particularly excited to be working on screening for TB and to help
deliver this to even the remotest of locations. We have the
potential here to build true access to healthcare for all in India.
Although we are looking at India initially, Qure.ai are a great
partner and their technologies hold just as much benefit here in
the UK and we are excited to explore a number of opportunities for
the technologies within the NHS and UK private market. "
Prashant Warier, CEO and co-founder of Qure.ai, said:
"We're happy to partner with Feedback to enable remote and
secure communications between frontline clinicians and their teams.
Together, our solutions help improve coordination and communication
to deliver quality diagnosis. Apart from TB, our technology detects
29 other abnormalities on chest X-rays. We plan to expand our
offerings to the UK and other parts of the world to improve lung
health diagnosis.
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas Johnson 07980 541 893 or 07748 325 236 or
07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical
communication products. Its core product, Bleepa, is a
revolutionary medical imaging communications app, providing an
easy-to-use, high quality tool to enable remote and secure
communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging
communications platform on the NHSx clinical communications tools
framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care providers. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of clinical
review.
About Qure.ai
Qure.ai is a breakthrough Artificial Intelligence (AI) solution
provider that is disrupting the radiology 'status quo' by enhancing
imaging accuracy and improving health outcomes with the assistance
of machine-supported tools. Qure.ai taps deep learning technology
to provide automated interpretation of radiology exams like X-rays,
CTs and MRI scans for time and resource-strapped medical imaging
professionals-enabling faster diagnosis and speed to treatment.
Qure.ai is helping to make healthcare more accessible and
affordable to patients worldwide.
Qure.ai technologies have received both FDA clearance and CE
marking.
About TB:
TB is an ancient disease that has affected mankind for more than
4,000 years. It is a chronic disease caused by the bacillus
Mycobacterium tuberculosis and spreads from person to person
through air. TB usually affects the lungs, but it can also affect
other parts of the body, such as brain, intestines, kidneys, or the
spine. TB remains a leading cause of morbidity and mortality in
developing countries, accounting for 7% of all deaths. It is the
first infectious disease declared by the World Health Organization
(WHO) as a global health emergency and in 2007, it was estimated
globally that there were 9.27 million incident cases of TB, 13.7
million prevalent cases.(1)
TB is major issue in countries across the world. It is hampered
by the fact that most radiology departments and specialists tend to
be based in cities, but it is a disease recognised for impacting
the poorest sections in the community, often in remote locations(1)
. In India alone, there were 2.64 million new cases of TB and
450,000 deaths in 2019, accounting for more than quarter of global
cases and deaths(2) .
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2980871/
2. https://gh.bmj.com/content/5/11/e003979
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFEFMDEFSEIU
(END) Dow Jones Newswires
September 14, 2021 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Okt 2023 bis Okt 2024